{"Abbreviation":["GBL"],"Adverse Effects":"Neurotoxin - Acute solvent syndrome","Aliases":["Butyrolactone","dihydrofuran-2(3H)-one","4-Butyrolactone","4-Butanolide","1,4-Butanolide","2-Oxolanone","4-Hydroxybutyric acid lactone","Butyrylactone","4-Deoxytetronic acid","Butyryl lactone","1,2-Butanolide","Dihydro-2(3H)-furanone","2(3H)-Furanone, dihydro-","Butyric acid lactone","Tetrahydro-2-furanone","BLON","γ-BL","4-Hydroxybutanoic acid lactone","Dihydro-2-furanone","1,4-Lactone","Agrisynth BLO","γ-Hydroxybutyric acid lactone","2-Oxotetrahydrofuran","γ-Hydroxybutyrolactone","γ-6480"],"Associated Disorders and Diseases":"Solvents, acute toxic effect [Category: Acute Poisoning]","Biological Half-Life":"Elimination half-life of 0.3 hours .. /after oral administration of 136 mg/kg bw/","Boiling Point":"399 to 401 °F at 760 mmHg (NTP, 1992)","CAS":"96-48-0","ChEBI":"CHEBI:42639","ChEMBL":"CHEMBL95681","ChemicalClasses":["carboxylic acid"],"Chirality":"achiral","Color/Form":"Oily liquid","Decomposition":"When heated to decomposition it emits acrid and irritating fumes.","Density":"1.1286 at 59 °F (NTP, 1992) - Denser than water; will sink g/cm\u003csup\u003e3\u003c/sup\u003e","Drug Warnings":"The Food and Drug Administration is alerting consumers not to purchase or consume products, some of which are labeled as dietary supplements, that contain gamma butyrolactone (abbreviated as GBL). FDA has also asked the companies that manufacture these products to voluntarily recall them. The agency has received reports of serious health problems -- some that are potentially life-threatening -- associated with the use of these products. Although labeled as dietary supplements, these products are illegally marketed unapproved new drugs. Products containing GBL are marketed under various brand names ... . They are promoted with claims to build muscles, improve physical performance, enhance sex, reduce stress and induce sleep.","EINECS":"202-509-5","Esters":[],"European Community (EC) Number":"202-509-5","Flash Point":"209 °F (NTP, 1992)","Formating":["gamma-butyrolactone"],"HMDB ID":"HMDB0000549","Health Effects":"CNS depression; amnesia and hypotonia. Rarely, hypertension, orthostatic hypotension, apnea, dyskinesias, dystonias, and hypomania occur.","HeavyAtomCount":6,"IUPACName":"oxolan-2-one","InChI":"InChI=1S/C4H6O2/c5-4-2-1-3-6-4/h1-3H2","InChIKey":"YEJRWHAVMIAJKC-UHFFFAOYSA-N","LC50":[{"dosages":[{"amount":"\u0026gt;5100 mg/m3/4H","route":"inhalation"}],"organism":"Rat"}],"LD50":[{"dosages":[{"amount":"1540 mg/kg","route":"oral"},{"amount":"1 gm/kg","route":"intraperitoneal"}],"organism":"Rat"},{"dosages":[{"amount":"1460 mg/kg","route":"oral"},{"amount":"1100 mg/kg","route":"intraperitoneal"}],"organism":"Mouse"},{"dosages":[{"amount":"\u0026gt;5 gm/kg","route":"skin"}],"organism":"Guinea pig"}],"LDLo":[{"dosages":[{"amount":"1600 mg/kg","route":"parenteral"}],"organism":"Mouse"},{"dosages":[{"amount":"500 mg/kg","route":"intravenous"}],"organism":"Rabbit"}],"MeSH Pharmacological Classification":"Liquids that dissolve other substances (solutes), generally solids, without any change in chemical composition, as, water containing sugar. (Grant \u0026amp; Hackh\u0026apos;s Chemical Dictionary, 5th ed)","Melting Point":"-49 °F (NTP, 1992)","MolecularFormula":"C\u003csub\u003e4\u003c/sub\u003eH\u003csub\u003e6\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"86.09 g/mol","Non-Human Toxicity Values":"LD50 MOUSE IV 880 MG/KG","Odor":"Pleasant odor","Physical Description":"4-butyrolactone is a clear colorless oily liquid with a pleasant odor. (NTP, 1992)","PubChemId":7302,"Record Description":["Wikipedia|List of designer drugs|Sedatives|GHB analogues"],"RefCount":3,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Gamma-Butyrolactone","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q79739","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB04699","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/7302","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL95681","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:42639","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=96-48-0","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0000549","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C01770","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/OL659KIY4X","Name":"γ-Butyrolactone","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6020224","Name":"γ-Butyrolactone","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 7302, γ-Butyrolactone. Accessed September 1, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/7302\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/7302\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. γ-Butyrolactone. UNII: OL659KIY4X. Global Substance Registration System. Accessed September 1, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/OL659KIY4X\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/OL659KIY4X\u003c/a\u003e"],"SMILES":"C1CC(=O)OC1","SaltData":[],"Salts":[],"Solubility":"greater than or equal to 100 mg/mL at 55 °F (NTP, 1992)","Stability/Shelf Life":"Stable at pH 7; rapidly hydrolyzed by bases, slowly hydrolyzed by acids.","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 42.944 27.551\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h43v28H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"M5.723 26.551h15.24M20.963 26.551l4.673-14.529\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m24.419 11.137 11.737-3.83M25.175 13.455l11.737-3.83\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m36.156 7.307-5.868 1.915M36.912 9.625l-5.868 1.915\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m25.636 12.022-9.203-6.693M10.244 5.335l-9.195 6.687M5.723 26.551 1.049 12.022\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M42.384 7.292q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.733 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M15.602 3.078q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.263-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881Q12.59.56 13.357.56q.733 0 1.233.316.5.309.756.875.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452\" class=\"atom\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m16.433 5.329 4.602 3.346M10.244 5.335 5.646 8.678\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"γ-Butyrolactone","Toxicity Data":"LD50: 17.2 mL/kg (Oral, Rat) (581)","Treatment":"In case of oral exposure, administer a benzodiazepine IV. There is no antidote. Treatment is symptomatic and supportive. (T36)\n","UNII":"OL659KIY4X","Wikidata":"Q79739","Wikipedia":"Gamma-Butyrolactone","XLogP":-0.6}